{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:51:13Z","timestamp":1783698673381,"version":"3.55.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The use of immune checkpoint inhibitors (ICIs) in the treatment of malignant tumors is becoming more widespread, and the management of immune-related adverse events (irAEs) has become an important concern in oncological treatments. Here we present a 44-year-old female patient with triple-negative breast cancer (TNBC), who developed severe nausea and vomiting symptoms after pembrolizumab treatment. Gastroscopy showed extensive exfoliation, redness, and swelling of the gastric mucosa. Histology suggested complete destruction of the gastric mucosa and a large number of immune cells infiltration. After excluding other differential diagnoses, we considered the diagnosis of immune checkpoint inhibitor-associated gastritis. In responding to methylprednisolone treatment, her symptoms improved, and a repeated gastroscopy suggested repair in gastric mucosa, but demonstrated autoimmune gastritis-like manifestations. This case report describes a rare case of ICI-mediated gastritis. The importance of early endoscopy is emphasized and hormonal therapy remains the mainstay of treatment for this patient.<\/jats:p>","DOI":"10.3389\/fonc.2025.1624185","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:15:29Z","timestamp":1760069729000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune-mediated gastritis in a patient with breast cancer due to therapy with immune checkpoint inhibitor pembrolizumab: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Yalan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0422","article-title":"The evolving role of immune checkpoint inhibitors in cancer treatment","volume":"20","author":"Pennock","year":"2015","journal-title":"Oncologist"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-331164","article-title":"RE.GA.IN.: the real-world gastritis initiative-updating the updates","volume":"73","author":"Rugge","year":"2024","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1443-1661.2012.01385.x","article-title":"Study Group for Establishing Endoscopic Diagnosis of Chronic Gastritis. Changes in endoscopic findings of gastritis after cure of H.\u2009pylori infection: multicenter prospective trial","volume":"25","author":"Kato","year":"2013","journal-title":"Dig Endosc"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1055\/a-2000-5705","article-title":"Immune-mediated Gastritis in a Patient with Metastatic Lung Cancer due to Therapy with the immune Checkpoint Inhibitor Pembrolizumab - Differences and Similarities in Comparison to \u201cendogenous\u201d autoimmune Type A Gastritis and a review of literature","volume":"61","author":"Ecker","year":"2023","journal-title":"Z Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000538006","article-title":"Lenvatinib combined with the PD-1 inhibitor camrelizumab in the treatment of primary liver cancer caused hemorrhagic exfoliative gastritis","volume":"17","author":"Chen","year":"2024","journal-title":"Case Rep Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.11.009","article-title":"An overlooked cause of severe gastritis","volume":"166","author":"Lan","year":"2024","journal-title":"gastroenterology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: a systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad031","article-title":"Characteristics of immune checkpoint inhibitor-associated gastritis: report from a major tertiary care center","volume":"28","author":"Farha","year":"2023","journal-title":"Oncologist"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1055\/a-1839-4303","article-title":"Severe immune checkpoint inhibitor-associated gastritis: a case series and literature review","volume":"10","author":"Sugiyama","year":"2022","journal-title":"Endosc Int Open"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/gastro\/goz065","article-title":"Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy","volume":"8","author":"Rajha","year":"2019","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34543","article-title":"Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course","volume":"129","author":"Haryal","year":"2023","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e008232","DOI":"10.1136\/jitc-2023-008232","article-title":"Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series","volume":"12","author":"Harvey","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e009742","DOI":"10.1136\/jitc-2024-009742","article-title":"Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events","volume":"12","author":"Shatila","year":"2024","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1624185\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:15:30Z","timestamp":1760069730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1624185\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":18,"alternative-id":["10.3389\/fonc.2025.1624185"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1624185","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"article-number":"1624185"}}